Title: DEVELOPMENT OF A RAPID CLINICAL SCREENING TEST FOR THE CYSTIC FIBROSIS GENE

PROJECT ADMINISTRATION DATA

OCA contact: Kathleen R. Ehlinger 894-4820

Sponsor technical contact

DR. ROBERT G. BEST
(803)765-7316

SCHOOL OF MEDICINE
TWO RICHLAND MEDICAL PARK, SUITE 301
UNIVERSITY OF SOUTH CAROLINA
COLUMBIA, S.C. 29208

Sponsor issuing office

DAN CHRISTMUS
(803)777-7093

UNIVERSITY OF SOUTH CAROLINA
OFFICE OF SPONSORED PROGRAMS
COLUMBIA, SC 29208

Security class (U,C,S,TS) : U
ONR resident rep. is ACO (Y/N) N
Defense priority rating : N/A
N/A supplemental sheet
Equipment title vests with: Sponsor X GIT

Administrative comments -
INITIATION OF PROJECT. NO INDIRECT COSTS ALLOWED. SEE PAGE 2 OF AGREEMENT.
NOTICE OF PROJECT CLOSEOUT

Closeout Notice Date 04/16/91

Project No. G-32-611

Project Director MATHIS J N

Sponsor UNIV OF SOUTH CAROLINA/COLUMBIA, SC

Contract/Grant No. AGREEMENT DTD 9/17/90

Prime Contract No.

Center No. 10/24-6-R7061-0A0

School/Lab BIOLOGY

Contract Entity GTRC

Title DEVELOPMENT OF A RAPID CLINICAL SCREENING TEST FOR THE CYSTIC FIBROSIS GE

Effective Completion Date 9/10/416 (Performance) 9/10/416 (Reports)

Closeout Actions Required:  

<table>
<thead>
<tr>
<th>Date</th>
<th>Y/N Submitted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td></td>
</tr>
</tbody>
</table>

Other

Comments

Subproject Under Main Project No.

Continues Project No.

Distribution Required:

<table>
<thead>
<tr>
<th></th>
<th>Y/N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Director</td>
<td>Y</td>
</tr>
<tr>
<td>Administrative Network Representative</td>
<td>Y</td>
</tr>
<tr>
<td>GTRI Accounting/Grants and Contracts</td>
<td>Y</td>
</tr>
<tr>
<td>Procurement/Supply Services</td>
<td>Y</td>
</tr>
<tr>
<td>Research Property Management</td>
<td>Y</td>
</tr>
<tr>
<td>Research Security Services</td>
<td>N</td>
</tr>
<tr>
<td>Reports Coordinator (OCA)</td>
<td>Y</td>
</tr>
<tr>
<td>GTRC</td>
<td>Y</td>
</tr>
<tr>
<td>Project File</td>
<td>Y</td>
</tr>
<tr>
<td>Other</td>
<td>N</td>
</tr>
</tbody>
</table>
Development of a Rapid Clinical Test for the Most Common Deletion Resulting in Cystic Fibrosis (ΔF508)

The primary objective of this grant was to set up a facility to perform DNA testing for the ΔF508 deletion responsible for 70% of cystic fibrosis (CF) mutations.

During June and July 1990, we developed polymerase chain reaction (PCR) methods for identification of the ΔF508 deletion. This involved synthesis and purification of a variety of oligonucleotide primers, determination of optimal reaction conditions, and isolation of DNA from the blood of CF carriers.

During July - September 1990, we set up a laboratory facility at the University of South Carolina, School of Medicine in Columbia, S.C. We adapted previously developed procedures for DNA isolation and PCR to fit with the equipment available in this facility. We set up the DNA thermocycler for PCR, gel electrophoresis equipment for separating DNA molecules and transilluminator and photosystem for detecting and identifying DNA in gels. During the start-up period of this project, we received 150 blood samples from children affected with CF and their immediate family members (parents and sibs).

From September 1990 - March 1991, diagnoses were developed on each of the patients by two techniques. One of the techniques involved the generation of a
Sau3A restriction site by a nucleotide mismatch (Friedman K. and J. Stoerker, Clin. Chem. 36:1702-1703) during PCR and the second involved hybridization of PCR products from a known homozygous normal individual with DNA from individuals of unknown status (Rommens et al., Am. J. Hum. Genet. 46: 396-397). Three other techniques were developed; one of these failed to be robust enough (Ballabio et al., Nature 343:220) and the other two are still in development (Golden et al., unpublished). Screening of blood samples revealed the following results from 43 affected CF patients 23 are homozygous for ΔF508, 15 are heterozygous and 5 are homozygous for other deletions. The carrier status of individuals related to these affected children has also been determined. All cases have been verified by at least two separate replicates with each of the two primary tests described above. None of the initial 150 patients whose blood was collected during the start-up phase of this project has been (or will be) billed for the laboratory work. The total value of services provided during this start-up phase will be approximately $22,500.00 (based on 150 patients with a test cost of $150.00). We are currently continuing studies to optimize testing methodology and test alternative methodologies. The two methodologies still being developed are different from other methods being used currently and may provide new technology for CF screening.